Global Med Technologies(R), Inc. Signs Purchase Agreement to Acquire Inlog, SA, a European Medical Software Firm

DENVER, March 31 /PRNewswire/ --

- Accretive Inlog Acquisition to Extend Global Med's Total Reach to 1,400 
Sites in 20 Countries

Global Med Technologies(R), Inc. ("Global Med" or the "Company") (OTC
Bulletin Board: GLOB), an international e-Health, medical information
technology company, today announced the signing of a Purchase Agreement to
acquire Inlog, SA, and its German and related subsidiaries ("Inlog"), a
private European medical software firm, for a maximum of US$11.5 million in a
combination of cash, stock and earnout. Inlog's shareholders must use
US$500,000 of the cash proceeds to purchase Global Med common stock in the
open market within three months of the closing. Inlog's unaudited revenues
for their fiscal year ended June 30, 2007 were approximately euro 7.3
million(i) or about US$11.4 million at current exchange rates, with EBITDA of
approximately euro 770,000(i) or approximately US$1.2 million. Global Med
will utilize a combination of existing cash and debt to pay for the
transaction.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040226/GLOBALMEDLOGO)

Inlog, based in Lyon, France, with additional operations in Grenoble,
France, Munich and Alzey, Germany, is a leading European provider of donor
center and transfusion information management systems as well as laboratory
information systems and other ancillary medical software systems. The
transaction is expected to close in the second quarter of 2008. Inlog's
management is planning to stay with the Company.

Chairman and CEO of Global Med Technologies, Inc., Michael I. Ruxin,
M.D., stated, "The acquisition of Inlog by Global Med is a transforming event
in the history of our Company." Dr. Ruxin continued, "At the completion of
this acquisition, we will truly be a global company, with blood and
laboratory software applications in 20 countries (in the US, Canada,
Caribbean, European Union, Africa, French Polynesia, and New Caledonia). This
includes 582 donor center sites, 458 hospital sites and 360 laboratories
world-wide, for a total of 1,400 sites. From our perspective, our high
quality people, productivity and services, coupled with our high-touch
philosophy to our current and future customers, through our Service 360(TM)
commitment, will continue to allow us to grow our Company in the global
marketplace." Dr. Ruxin added, "The structure of this transaction is expected
to be accretive, exclusive of financing costs, in the first full year of
operations. This acquisition is strategically important to Global Med as the
international marketplace provides a platform for Global Med's continued
growth."

Inlog's product line consists of five primary products: EdgeBlood(ii)
(also known as CTS Serveur, for the donor center marketplace), EdgeTrack(ii)
(for the hospital transfusion marketplace), EdgeLab (Laboratory Information
System "LIS"), EdgeCell (Cellular Therapy for tissue banks, stem cell centers
and cord blood centers), and SAPA (supports regulatory compliance and
document management). Inlog is ISO 9001:2000 certified and their products
have received the NF/ISO 25051/12119 certification guaranteeing the highest
level of quality regarding the design, the testing and validation of the
software, the documentation quality and the quality of support and
maintenance.

Inlog has been developing, implementing, and supporting its blood bank
information management solutions since 1992 with over 700 sites in 15
countries using its own products. Inlog recently completed the national
installation of its EdgeBlood product in France. All 2.2 million French blood
donations flow through Inlog's products in France including blood
collections, infectious disease testing, component manufacturing and
distribution. In addition to France, Inlog has substantial blood center and
transfusion market share in Germany, Austria, Belgium and Switzerland, as
well as installations in Greece and Monaco. Some of Inlog's notable clients
are the French Blood Establishment (Etablissement Français du Sang), the
Bade-Württemberg-Hessen Red Cross, the Bavarian Red Cross, the Vienna
Transfusion Center, the HUG ZURICH Transfusion Center, the Belgium-Flandres
Red Cross, the Pierre & Marie Curie Institute in Paris, and CRLAC Antoine
Lacassagne Cancer Center of Nice. In Africa, Inlog supplies its blood center
and transfusion systems to the National Blood Services of Gabon, Burkina Faso
and Senegal, as well as having installations in Algeria, the Ivory Coast and
Rwanda.

Inlog's EdgeLab, a laboratory information system (LIS), has been rapidly
gaining market share in France with 130 laboratory sites. This recently
developed LIS is a best-of-breed application which is gaining market share in
Germany, Spain, Belgium, the Middle East and Asia. As few as four years ago,
Inlog had virtually no market share in the LIS marketplace in France. Now,
Inlog has garnered 15% of the marketplace, an area of strong revenue growth.

Thomas F. Marcinek, the Company's President and COO, stated, "Inlog's
capability and experience in handling international implementations including
France which processes millions of donations per year, opens up new markets
and opportunities for Global Med. We see a need in the global marketplace for
a company with proven blood bank products, experience with national
implementations, multi-lingual applications, and strong service offerings
that are financially sound and well capitalized. Together with Inlog, we
believe that Global Med is strategically poised and will aggressively market
these strengths to potential customers around the world which will continue
to expand our market share." Mr. Marcinek added, "Global Med, through its
Service 360(TM) Program, maintains its focus on our valuable customer base.
With the addition of the Inlog customer base, we will continue to improve our
customer support, service offerings and products as we grow."

Renaud Blanc-Bernard, the CEO of Inlog, commented, "On behalf of Inlog,
we are all very excited about the synergies between our two companies. We
truly believe that the combined Global Med/Inlog Company will become a global
leader in donor center and transfusion medicine software. Together we believe
that we will gain economies of scale that will enable our products to evolve
in sync with the rapidly changing international blood center, transfusion
service and laboratory marketplace. We are also excited for our customers who
will gain access to new products and services. This is truly a win-win for
Global Med, Inlog, our employees, our combined substantial international
customer base and the industry."

The Purchase Agreement also requires that certain conditions be met prior
to the closing of this transaction. (See the 8-K filed today on this
transaction.)

About Global Med Technologies, Inc.

Global Med Technologies(R), Inc. is an international e-Health medical
information technology company providing information management software
products and services to the healthcare industry. Its Wyndgate
Technologies(R) division is a leading supplier of information management
systems to U.S. and international blood centers and hospital transfusion
centers. Each year, Wyndgate's products and services manage more than eight
million blood components, representing over 27% of the U.S. blood supply.
Wyndgate's products are also being used in Canada, Africa, and the Caribbean.
Wyndgate's software provides Vein-to-Vein(R) tracking from donor collection
to patient transfusion through its Donor Doc(TM) interactive donor health
history questionnaire, ElDorado Donor(TM) and SafeTrace(R) donor management
systems, to its SafeTrace Tx(R) advanced transfusion management system.
Global Med's PeopleMed(R), Inc. subsidiary provides custom software
validation, consulting and compliance solutions to hospitals and blood
centers. PeopleMed's in-depth knowledge of Wyndgate's products and the blood
banking industry results in cost-effective validation services, which leads
to more efficient software implementations and upgrades for our customers.

For more information about Global Med's products and services, please
call +1-800-WYNDGATE or visit http://www.globalmedtech.com,
http://www.peoplemed.com and http://www.wyndgate.com.

This news release may include statements that constitute forward-looking
statements, usually containing the words "believe," "estimate," "project,"
"expects" or similar expressions. These statements are made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform Act of
1995. Forward-looking statements inherently involve risks and uncertainties
that could cause actual results to differ materially from the forward-looking
statements. By making these forward-looking statements, the Company
undertakes no obligation to update these statements for revisions or changes
after the date of this news release.

(i)  The information provided herein represents unaudited non-GAAP
         information and may be subject to change. In addition, certain 
         discontinued operations and non-recurring expenses have been 
         eliminated. The Company believes the preparation of this non-GAAP 
         information may be helpful to investors in determining what the 
         current year's and future year's results may or would look like for 
         Inlog.

    (ii) FDA 510(k) clearance required prior to sales in the U.S.



Web site: http://www.globalmedtech.com